201286-99-9

Basic information

• Product Name: 6-Hydroxy-3-methylindazole
• Synonyms: 6-Hydroxy-3-methylindazole;3-Methylindazol-6-ol
• CAS NO: 201286-99-9
• Molecular Formula: C₈H₈N₂O
• Molecular Weight: 148.16
• Mol File: 201286-99-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 366.002 °C at 760 mmHg
• Flash Point: 175.152 °C
• Appearance: /
• Density: 1.349 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.719
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 9.26±0.40(Predicted)
• CAS DataBase Reference: 6-Hydroxy-3-methylindazole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Hydroxy-3-methylindazole(201286-99-9)
• EPA Substance Registry System: 6-Hydroxy-3-methylindazole(201286-99-9)

Safety Data

• Hazardous Substances Data: 201286-99-9(Hazardous Substances Data)

Usage

General Description

6-Hydroxy-3-methylindazole is a synthetic chemical compound that falls under the category of organic compounds known as indazoles, which are aromatic heterocyclic compounds containing a benzene and a pyrazole ring fused together. Known for its molecular formula C9H8N2O, it usually appears as a crystalline solid. The applications of this chemical are not widely specified, however, typically, substances within the indazole class are used in the pharmaceutical industry, agricultural applications, and for research purposes such as material science and biological studies. Factors such as solubility, toxicity, and reactivity of the 6-Hydroxy-3-methylindazole depend on its physical and chemical properties, and should be handled based on the standard safety guidelines for chemicals.

InChI:InChI=1/C8H8N2O/c1-5-7-3-2-6(11)4-8(7)10-9-5/h2-4,11H,1H3,(H,9,10)

Upstream product

• 79173-62-9 3-methyl-1H-indazol-6-amine 
• 74457-86-6 1-(2-fluoro-4-methoxyphenyl)-1-ethanone 
• 98619-07-9 1-(2-fluoro-4-hydroxyphenyl)ethanone 
• 7732-18-5 water 
• 7746-29-4 6-methoxy-3-methyl-1H-indazole 
• 519158-44-2 1-benzyl-3-methyl-1H-indazol-6-ol 
• 6494-19-5 3-methyl-6-nitro-1H-indazole 

Downstream Products

• 201286-96-6 3-methyl-indazole-6-carboxylic acid 
• 1283128-42-6 tert-butyl (R)-(2-(3-(cyclopentanesulfonamido)phenyl)-2-hydroxyethyl)(2-((3-methyl-1H-indazol-6-yl)oxy)ethyl)carbamate 
• 1283128-39-1 (R)-tert-butyl 6-(2-(tert-butoxycarbonyl-(2-(3-(2-fluorophenylsulfonamide)phenyl)-2-(triethylsilyloxy)ethyl)amino)ethoxy)-3-methylindazole-1-carboyxlate 
• 1283126-47-5 (R)-tert-butyl 6-(2-(tert-butoxycarbonyl-(2-(3-(4-chloro-3-nitrophenylsulfonamide)phenyl)-2-(triethylsilyloxy)ethyl)amino)ethoxy)-3-methylindazole-1-carboxylate 
• 1283126-30-6 (R)-tert-butyl 6-(2-(tert-butoxycarbonyl-(2-(3-(3-nitrophenylsulfonamide)phenyl)-2-(triethylsilyloxy)ethyl)amino)ethoxy)-3-methylindazole-1-carboxylate 
• 1283126-28-2 (R)-tert-butyl 6-(2-((2-(3-(3-aminophenylsulfonamide)phenyl)-2-(triethylsilyloxy)ethyl)(tert-butoxycarbonyl)amino)ethoxy)-3-methylindazole-1-carboxylate 
• 1221179-03-8 C₂₉H₃₄N₂O₃Si 
• 1221179-43-6 (R)-tert-butyl 6-(2-((2-(3-amino-4-chlorophenyl)-2-hydroxyethyl)(tert-butoxycarbonyl)amino)ethoxy)-3-methylindazole-1-carboxylate 
• 1221179-42-5 (R)-tert-butyl 6-(2-((2-(3-amino-4-chlorophenyl)-2-hydroxyethyl)(benzyl)amino)ethoxy)-3-methylindazole-1-carboxylate 
• 1221179-41-4 (R)-tert-butyl 6-(2-(benzyl(2-(4-chloro-3-nitrophenyl)-2-hydroxyethyl)amino)ethoxy)-3-methylindazole-1-carboxylate 
• 1221179-38-9 (R)-tert-butyl 6-(2-(benzyl(2-(4-fluoro-3-nitrophenyl)-2-hydroxyethyl)amino)ethoxy)-3-methyl indazole-1-carboxylate 

Relevant articles and documents

Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects

Novel indazole derivatives were prepared and evaluated for their biological activity and cardiovascular safety profile as human β3-adrenergic receptor (AR) agonists. Although the initial hit compound 5 exhibited significant β3-AR agonistic activity (EC50 = 21 nM), it also exhibited agonistic activity at the α1A-AR (EC50 = 219 nM, selectivity: α1A/β3 = 10-fold). The major metabolite of 5, which was an oxidative product at the indazole 3-methyl moiety, gave a clue to a strategy for improvement of the selectivity for β3-AR agonistic activity versus α1A-AR agonistic activity. Thus, modification of the 3-substituent of the indazole moiety effectively improved the selectivity to develop compound 11 with potent β3-AR agonistic activity (EC50 = 13 nM) and high selectivity (α1A/β3 = >769-fold). Compound 11 was also inactive toward β1 and β2-ARs and showed dose dependent β3-AR mediated relaxation of marmoset urinary bladder smooth muscle, while it did not obviously affect heart rate or blood pressure (iv, 3 mg/kg) in anesthetized rats.

INDAZOLE COMPOUNDS

Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have 133 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.

SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.